These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 37483851)

  • 21. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes.
    Preisser F; Chun FKH; Pompe RS; Heinze A; Salomon G; Graefen M; Huland H; Tilki D
    Eur Urol; 2019 Jul; 76(1):106-114. PubMed ID: 30772034
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study.
    Ploussard G; Staerman F; Pierrevelcin J; Larue S; Villers A; Ouzzane A; Bastide C; Gaschignard N; Buge F; Pfister C; Bonniol R; Rebillard X; Fadli S; Mottet N; Saint F; Saad R; Beauval JB; Roupret M; Audenet F; Peyromaure M; Delongchamps NB; Vincendeau S; Fardoun T; Rigaud J; Soulie M; Salomon L;
    World J Urol; 2014 Oct; 32(5):1331-8. PubMed ID: 24270970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy.
    Tilki D; Preisser F; Tennstedt P; Tober P; Mandel P; Schlomm T; Steuber T; Huland H; Schwarz R; Petersen C; Graefen M; Ahyai S
    BJU Int; 2017 May; 119(5):717-723. PubMed ID: 27743493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prostate-specific antigen after salvage radiotherapy for postprostatectomy biochemical recurrence predicts long-term outcome including overall survival.
    Bartkowiak D; Thamm R; Bottke D; Siegmann A; Böhmer D; Budach V; Wiegel T
    Acta Oncol; 2018 Mar; 57(3):362-367. PubMed ID: 28816074
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline.
    Thompson IM; Valicenti RK; Albertsen P; Davis BJ; Goldenberg SL; Hahn C; Klein E; Michalski J; Roach M; Sartor O; Wolf JS; Faraday MM
    J Urol; 2013 Aug; 190(2):441-9. PubMed ID: 23707439
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of androgen deprivation and salvage radiation therapy for patients with prostate cancer and biochemical recurrence after prostatectomy.
    Ghadjar P; Aebersold DM; Albrecht C; Böhmer D; Flentje M; Ganswindt U; Höcht S; Hölscher T; Sedlmayer F; Wenz F; Zips D; Wiegel T;
    Strahlenther Onkol; 2018 Jul; 194(7):619-626. PubMed ID: 29383406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial.
    Pollack A; Karrison TG; Balogh AG; Gomella LG; Low DA; Bruner DW; Wefel JS; Martin AG; Michalski JM; Angyalfi SJ; Lukka H; Faria SL; Rodrigues GB; Beauchemin MC; Lee RJ; Seaward SA; Allen AM; Monitto DC; Seiferheld W; Sartor O; Feng F; Sandler HM
    Lancet; 2022 May; 399(10338):1886-1901. PubMed ID: 35569466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Salvage radiation therapy for prostate specific antigen progression following radical prostatectomy: 10-year outcome estimates.
    Pazona JF; Han M; Hawkins SA; Roehl KA; Catalona WJ
    J Urol; 2005 Oct; 174(4 Pt 1):1282-6. PubMed ID: 16145393
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
    Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
    Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contemporary Update of a Multi-Institutional Predictive Nomogram for Salvage Radiotherapy After Radical Prostatectomy.
    Tendulkar RD; Agrawal S; Gao T; Efstathiou JA; Pisansky TM; Michalski JM; Koontz BF; Hamstra DA; Feng FY; Liauw SL; Abramowitz MC; Pollack A; Anscher MS; Moghanaki D; Den RB; Stephans KL; Zietman AL; Lee WR; Kattan MW; Stephenson AJ
    J Clin Oncol; 2016 Oct; 34(30):3648-3654. PubMed ID: 27528718
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of early salvage radiotherapy at PSA < 0.5 ng/ml and impact of post-SRT PSA nadir in post-prostatectomy recurrent prostate cancer.
    Bottke D; Bartkowiak D; Siegmann A; Thamm R; Böhmer D; Budach V; Wiegel T
    Prostate Cancer Prostatic Dis; 2019 May; 22(2):344-349. PubMed ID: 30487644
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessing radiation dose for postoperative radiotherapy in prostate cancer: Real world data.
    Hervás-Morón A; Domínguez-Rullán J; Santana VD; Valero M; Vallejo C; Sancho S; Fuentes JDG; López-Campos F; Gallego MC
    World J Clin Oncol; 2022 Jul; 13(7):652-662. PubMed ID: 36157159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Single tertiary cancer center experience on the management of pT3b prostate cancer after robotic-assisted laparoscopic prostatectomy.
    Nayak A; El-Taji O; Sukumar S; Piedad J; Ghose A; Hughes R; Alonzi R; Ostler P; Sharma A; Lane T; Adshead J; Vasdev N
    Curr Urol; 2022 Dec; 16(4):227-231. PubMed ID: 36714225
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Variation in the use of postoperative radiotherapy among high-risk patients following radical prostatectomy.
    Morgan TM; Hawken SR; Ghani KR; Miller DC; Feng FY; Linsell SM; Salisz JA; Gao Y; Montie JE; Cher ML
    Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):216-21. PubMed ID: 26951715
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Outcome after PSMA-PET/CT-based salvage radiotherapy for nodal recurrence after radical prostatectomy.
    Rogowski P; Trapp C; von Bestenbostel R; Eze C; Ganswindt U; Li M; Unterrainer M; Zacherl MJ; Ilhan H; Beyer L; Kretschmer A; Bartenstein P; Stief C; Belka C; Schmidt-Hegemann NS
    Eur J Nucl Med Mol Imaging; 2022 Mar; 49(4):1417-1428. PubMed ID: 34628521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIFU as salvage first-line treatment for palpable, TRUS-evidenced, biopsy-proven locally recurrent prostate cancer after radical prostatectomy: a pilot study.
    Asimakopoulos AD; Miano R; Virgili G; Vespasiani G; Finazzi Agrò E
    Urol Oncol; 2012 Sep; 30(5):577-83. PubMed ID: 21292508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiotherapy after radical prostatectomy for adenocarcinoma of the prostate: a UK institutional experience and review of published studies.
    Hudson E; Kynaston H; Varma M; Carter A; Staffurth J; Barber J; Mason MD; Lester JF
    Clin Oncol (R Coll Radiol); 2008 Jun; 20(5):353-7. PubMed ID: 18407476
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcomes after high-dose postprostatectomy salvage radiation treatment.
    Goenka A; Magsanoc JM; Pei X; Schechter M; Kollmeier M; Cox B; Scardino PT; Eastham JA; Zelefsky MJ
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):112-8. PubMed ID: 22300563
    [TBL] [Abstract][Full Text] [Related]  

  • 39. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
    Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
    Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative prostate-specific antigen after radical prostatectomy: to irradiate or not?
    Choo R; Hruby G; Hong J; Hong E; DeBoer G; Danjoux C; Morton G; Klotz L; Bhak E; Flavin A
    Int J Radiat Oncol Biol Phys; 2002 Mar; 52(3):674-80. PubMed ID: 11849789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.